Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Schlick Konstantin |
** = Publikationen gelistet in SCI/SSCI/Pubmed
2022
Originalarbeit (Zeitschrift)
** Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645
Doi: 10.1055/a-1548-4847
Web of Science
PubMed
FullText
FullText_MUG
2021
Originalarbeit (Zeitschrift)
** Müller, M; Posch, F; Kiem, D; Barth, D; Horvath, L; Stotz, M; Schaberl-Moser, R; Pichler, M; Greil, R; Jost, PJ; Seeber, A; Amann, A; Schlick, K; Gerger, A; Riedl, JM
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Ther Adv Med Oncol. 2021; 13:17588359211039930
Doi: 10.1177/17588359211039930
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Abstract (Zeitschrift)
** Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis.
ONCOL RES TREAT. 2020; 43(SUPPL 4):215-215.
[Poster]
Web of Science
** Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis.
WIEN KLIN WOCHENSCHR. Abstracts 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):78-79.-51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA.
[Poster]
Web of Science
** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
ANN ONCOL. 2020; 31: S942-S942.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2013
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM
Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX.
ANN ONCOL. 2020; 31: S949-S950.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2035
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
2019
Originalarbeit (Zeitschrift)
** Lembeck, AL; Posch, F; Klocker, EV; Szkandera, J; Schlick, K; Stojakovic, T; Kornprat, P; Lackner, C; Gerger, A; Stoeger, H; Stotz, M; Pichler, M
Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer.
Clin Chem Lab Med. 2019; 57(5):740-744
Doi: 10.1515/cclm-2018-0016
Web of Science
PubMed
FullText
FullText_MUG
2018
Originalarbeit (Zeitschrift)
** Asamer, E; Szkandera, J; Gibiser, P; Lembeck, AL; Stojakovic, T; Kornprat, P; Lackner, C; Winder, T; Schlick, K; Stöger, H; Gerger, A; Pichler, M; Stotz, M
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis.
Wien Klin Wochenschr. 2018; 130(19-20):569-574
Doi: 10.1007/s00508-018-1383-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2017
Originalarbeit (Zeitschrift)
** Pleyer, L; Döhner, H; Dombret, H; Seymour, JF; Schuh, AC; Beach, CL; Swern, AS; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Sperr, WR; Hojas, S; Rogulj, IM; Andel, J; Greil, R
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Int J Mol Sci. 2017; 18(2):
Doi: 10.3390/ijms18020415
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Abstract (Zeitschrift)
** Winder, T; Posch, F; Asamer, E; Stotz, M; Siebenhuner, A; Schlick, K; Magnes, T; Samaras, P; Szkandera, J; Clavien, PA; Neureiter, D; Greil, R; Pestalozzi, BC; Stoeger, H; Gerger, A; Egle, A; Pichler, M
An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK.
Doi: 10.1093/annonc/mdw371.77
[Poster]
Web of Science
FullText
FullText_MUG
2015
Originalarbeit (Zeitschrift)
** Troppan, KT; Melchardt, T; Deutsch, A; Schlick, K; Stojakovic, T; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Egle, A; Pichler, M
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Eur J Haematol. 2015; 95(6):538-544
Doi: 10.1111/ejh.12529
Web of Science
PubMed
FullText
FullText_MUG
2014
Originalarbeit (Zeitschrift)
** Troppan, KT; Schlick, K; Deutsch, A; Melchardt, T; Egle, A; Stojakovic, T; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Pichler, M
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
Br J Cancer. 2014; 111(1):55-60
Doi: 10.1038/bjc.2014.277
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome
BLOOD. 2014; 124(21):
Doi: 10.1182/blood.V124.21.2284.2284
Web of Science
FullText
FullText_MUG
** Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry
BLOOD. 2014; 124(21):
Web of Science
** Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry
BLOOD. 2014; 124(21):
Web of Science
** Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes
BLOOD. 2014; 124(21):
Web of Science
** Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstoker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry
BLOOD. 2014; 124(21):
Doi: 10.1182/blood.V124.21.3681.3681
Web of Science
FullText
FullText_MUG
2012
Originalarbeit (Zeitschrift)
** Schlick, K; Aigelsreiter, A; Pichler, M; Reitter, S; Neumeister, P; Hoefler, G; Beham-Schmid, C; Linkesch, W
Histiocytic sarcoma - targeted therapy: novel therapeutic options? A series of 4 cases.
Onkologie. 2012; 35(7-8):447-450
Doi: 10.1159/000340066
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
2011
Originalarbeit (Zeitschrift)
** Schlick, K; Regauer, S; Beham-Schmid, C; Cerroni, L; Rohn, A; Deutsch, AJ; Linkesch, W; Neumeister, P; Aigelsreiter, A
Pyoderma gangrenosum heralding acute leukemia for months: diagnostic hint written on the skin.
J Clin Oncol. 2011; 29(17): e506-e508.
Doi: 10.1200/JCO.2010.34.3855
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Editorial
** Schlick, K; Schilcher, G; Krisper, P; Neumeister, P; Linkesch, W; Beham-Schmid, C; Aigelsreiter, A
Spontaneous Tumor Lysis Syndrome Presenting As Acute Renal Failure in an Adult With De Novo Aleukemic T-ALL: Value of Renal Biopsy?
J CLIN ONCOL. 2011; 29(17): E494-E496.
Doi: 10.1200/JCO.2010.33.1504
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG